The Manila Times

Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)

Cosentyx® (secukinumab) achieved statistically significant and clinically meaningful sustained remission vs placebo at Week 521Trial showed reduction in annual cumulative steroid dose vs placebo ...
The Clinton Herald

TO YOUR GOOD HEALTH: Dentist catches squamos cell carcinoma during a routine visit

I am a healthy 69-year-old female. I walk every day and belong to an exercise group that I attend twice a week. I’m writing ...

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients …

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating ...
FierceBiotech

Fierce Biotech Fundraising Tracker '25: Adcytherix adds $122M; Peptilogics pumps up with $78M

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. We're maintaining the criteria we used for last year's ...

KEYTRUDA® (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of Non-Small Cell Lung Cancer (NSCLC)

KEYTRUDA is indicated for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then ...
BMJ

Neurological immune-related adverse events with checkpoint inhibitor therapy: challenges for the neurologist

Small case series or well-described case reports also document painful mononeuritis multiplex and ICI-related sensory neuronopathy with and without anti-Hu (paraneoplastic) antibodies.